Please assess the completion status of the following clinical trial:

Trial Title: IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tumor classified as stage I-IV located in oropharynx, hypopharynx, larynx (not glottic stage I-II), or oral cavity according to the TNM classification.~* Histopathological diagnosis of invasive squamous cell carcinoma in the primary tumor.~* Informed consent according to the Helsinki declaration and local regula-tions.~* The patient must be candidate for external beam radical radiotherapy, and must be expected to accomplish the treatment.~* Performance status 0-2 according to WHO criteria.~* The patient should not have symptoms of peripheral neuropathy assessed by clinical examination.~* Normal function of liver and kidney by routine laboratory examinations. The patient must not be pregnant~Exclusion Criteria:~* Distant metastases.~* The patient should not be in a state or condition that could be expected to influence the outcome of treatment, or complicate the assessment or the treatment follow-up, or (apart from the present disease) reduce the life expectancy.~* Surgical excision (except biopsy), prior or planned (including elective neck dissection).~* The existence of synchronous multiple malignancies (not leukoplakia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accl. RT (Type: ACTIVE_COMPARATOR): Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
- Accl. RT + Nimorazole (Type: EXPERIMENTAL): Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole

Based on this trial design, predict the completion outcome and termination type (if applicable).